Latest News
Merz Therapeutics and Kvvit sign exclusive agreement for INBRIJA in Greater China
26 May 2026 - Neurology specialist Merz Therapeutics GmbH and its Chinese partner Jiangxi Kvvit Pharmaceutical Co Ltd on Tuesday announced an exclusive licence and collaboration agreement for INBRIJA (levodopa inhalation powder) and its proprietary i...
OncoZenge secures European approval for Phase III BEAM-Pain trial of BupiZenge
26 May 2026 - Swedish pharmaceutical company OncoZenge AB (Nasdaq First North Growth Market:ONCOZ) announced on Tuesday that it has received European regulatory approval to initiate its pivotal Phase III BEAM-Pain trial of BupiZenge (BZ003) for oral ...
AstraZeneca's Enhertu recommended for EU approval in HER2-positive solid tumours
...
Transgene to present preclinical TG-MVA mpox vaccine data at World Congress on Infectious Diseases
26 May 2026 - French biotech company Transgene (Euronext Paris:TNG) announced on Tuesday that it will present new preclinical data on its TG-MVA prophylactic vaccine candidates against mpox at the World Congress on Infectious Diseases in Barcelona.Th...
Lundbeck's Vyepti (eptinezumab) receives South Korean approval for preventive treatment of migraine
26 May 2026 - Danish biopharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) announced on Tuesday that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted marketing authorisation for eptinezumab for use in adults with migraine.Affec...